AbstractRecent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC) have shown promising results. This multicenter, randomized, open-label phase 3 trial aimed to further assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy followed by adjuvant camrelizumab, compared to neoadjuvant chemotherapy alone.

摘要最近的单臂研究涉及PD-1抑制剂新辅助camrelizumab，加上可切除局部晚期食管鳞状细胞癌（LA-ESCC）的化疗，已显示出有希望的结果。这项多中心，随机，开放标签的3期临床试验旨在进一步评估新辅助camrelizumab加化疗后辅助camrelizumab与单独新辅助化疗相比的疗效和安全性。

A total of 391 patients with resectable thoracic LA-ESCC (T1b-3N1-3M0 or T3N0M0) were stratified by clinical stage (I/II, III or IVA) and randomized in a 1:1:1 ratio to undergo two cycles of neoadjuvant therapy. Treatments included camrelizumab, albumin-bound paclitaxel and cisplatin (Cam+nab-TP group; n = 132); camrelizumab, paclitaxel and cisplatin (Cam+TP group; n = 130); and paclitaxel with cisplatin (TP group; n = 129), followed by surgical resection.

共有391例可切除的胸部LA-ESCC患者（T1b-3N1-3M0或T3N0M0）按临床分期（I/II，III或IVA）进行分层，并以1:1:1的比例随机接受两个周期的新辅助治疗。治疗包括camrelizumab，白蛋白结合紫杉醇和顺铂（Cam+nab-TP组；n=132）；camrelizumab，紫杉醇和顺铂（Cam+TP组；n=130）；紫杉醇联合顺铂（TP组；n=129），然后手术切除。

Both the Cam+nab-TP and Cam+TP groups also received adjuvant camrelizumab. The dual primary endpoints were the rate of pathological complete response (pCR), as evaluated by a blind independent review committee, and event-free survival (EFS), as assessed by investigators. This study reports the final analysis of pCR rates.

Cam+nab-TP和Cam+TP组也接受佐剂camrelizumab。双主要终点是由盲人独立审查委员会评估的病理完全缓解率（pCR）和研究人员评估的无事件生存率（EFS）。这项研究报告了pCR率的最终分析。

In the intention-to-treat population, the Cam+nab-TP and Cam+TP groups exhibited significantly higher pCR rates of 28.0% and 15.4%, respectively, compared to 4.7% in the TP group (Cam+nab-TP versus TP: difference 23.5%, 95% confidence interval (CI) 15.1–32.0, P < 0.0001; Cam+TP versus TP: difference 10.9%, 95% CI 3.7–18.1, P = 0.0034).

在意向治疗人群中，Cam+nab-TP和Cam+TP组的pCR率分别为28.0%和15.4%，而TP组为4.7%（Cam+nab-TP与TP：差异23.5%，95%置信区间（CI）15.1-32.0，P<0.0001；Cam+TP与TP：差异10.9%，95%CI 3.7-18.1，P=0.0034）。

The study met its primary endpoint of pCR; however, EFS is not yet mature. The incidence of grade ≥3 treatment-related adverse events during neoadjuvant treatment was 34.1% for the Cam+nab-TP group, 29.2% for the Cam+TP group and 28.8% .

该研究达到了pCR的主要终点；但是，EFS尚未成熟。新辅助治疗期间≥3级治疗相关不良事件的发生率Cam+nab-TP组为34.1%，Cam+TP组为29.2%，28.8%。

MainEsophageal cancer is a significant global health issue, ranking seventh in incidence and sixth in mortality among all cancers1, with over half of the global esophageal squamous cell carcinoma (ESCC) cases in China2. In East Asia, neoadjuvant chemotherapy or chemoradiotherapy is standard for resectable locally advanced ESCC (LA-ESCC), with chemotherapy more prevalent3,4.

主要食管癌是一个重要的全球健康问题，在所有癌症中发病率排名第七，死亡率排名第六，中国超过一半的全球食管鳞状细胞癌（ESCC）病例2。在东亚，新辅助化疗或放化疗是可切除的局部晚期ESCC（LA-ESCC）的标准，化疗更为普遍3,4。

Studies such as CROSS and NEOCRTEC5010 highlight neoadjuvant chemoradiotherapy’s survival benefits over surgery alone5,6, whereas the JCOG9907 trial shows neoadjuvant chemotherapy improves overall survival (OS) compared to adjuvant therapy7. Recent phase 3 trials, including CMISG1701 and JCOG1109 (refs.

CROSS和NEOCRTEC5010等研究强调了新辅助放化疗相对于单独手术的生存益处[5,6]，而JCOG9907试验显示，与辅助治疗相比，新辅助化疗可改善总生存期（OS）[7]。最近的3期试验，包括CMISG1701和JCOG1109（参考文献）。

8,9), along with a network meta-analysis of randomized controlled trials10, have not demonstrated a significant OS advantage when comparing neoadjuvant chemoradiotherapy to chemotherapy for LA-ESCC, leaving the optimal neoadjuvant treatment strategy in question.Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of ESCC.

8,9），以及随机对照试验的网络荟萃分析10，在比较新辅助放化疗和LA-ESCC化疗时，尚未显示出显着的OS优势，因此最佳的新辅助治疗策略存在疑问。免疫检查点抑制剂（ICI）彻底改变了ESCC的治疗方法。

Camrelizumab, a PD-1 inhibitor, has demonstrated promising efficacy and safety in advanced ESCC, including both chemotherapy-refractory and treatment-naive cases, as evidenced by the ESCORT and ESCORT-1st studies11,12. Following these results, China has approved camrelizumab as a second-line monotherapy for advanced or metastatic ESCC, and in combination with chemotherapy (paclitaxel and cisplatin, TP) as a first-line treatment.

Camrelizumab是一种PD-1抑制剂，在晚期ESCC中显示出有希望的疗效和安全性，包括化疗难治性和未接受治疗的病例，这一点已被ESCORT和ESCORT-1st研究所证实[11,12]。根据这些结果，中国已批准卡姆雷珠单抗作为晚期或转移性ESCC的二线单药治疗，并与化疗（紫杉醇和顺铂，TP）联合作为一线治疗。

Several phase 1b and 2 trials assessing neoadjuvant immunotherapy with camrelizumab and chemotherapy for LA-ESCC report high pathological complete response (pCR) rates of 17.6% to 39.2% (refs. 13,14,15,16,17,18). Our latest retrospective analysis suggests that neoadjuvant chemotherapy plus immunotherapy showed better 3-year OS rates (91.7% ve.

。我们最近的回顾性分析表明，新辅助化疗加免疫治疗显示出更好的3年OS率（91.7%ve）。

Data availability

数据可用性

Due to intellectual property and confidentiality obligations, individual deidentified participant data that underlie the results reported in this article can be requested 24 months after study completion. Qualified researchers must submit a proposal to the corresponding author at liyin@cicams.ac.cn, outlining the reasons for requesting the data.

由于知识产权和保密义务，可以在研究完成后24个月要求提供本文报告结果的个人身份不明参与者数据。合格的研究人员必须向通讯作者提交提案liyin@cicams.ac.cn，概述请求数据的原因。

The leading clinical site and sponsor will review the request to ensure compliance with intellectual property and confidentiality obligations and will respond within two weeks. A signed data access agreement with the sponsor is required before any data can be shared. The study protocol and statistical analysis plan are available alongside the published article..

领先的临床网站和赞助商将审查该请求，以确保遵守知识产权和保密义务，并将在两周内做出回应。在共享任何数据之前，需要与赞助商签署数据访问协议。研究方案和统计分析计划与已发表的文章一起提供。。

Code availability

代码可用性

No custom code was used for data analysis in this study.

。

ReferencesSung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021).Article

ReferencesSung，H.等人，《2020年全球癌症统计：全球癌症协会对185个国家36种癌症的全球发病率和死亡率的估计》。CA Cancer J.Clin。71209-249（2021）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl Cancer Center 4, 47–53 (2024).Article

Han，B.等人，《中国癌症发病率和死亡率》，2022年。J、 Natl癌症中心4，47-53（2024）。文章

Google Scholar

谷歌学者

Chinese National Cancer Center; Chinese Association of Thoracic Surgeons; Chinese Society for Thoracic and Cardiovascular Surgery; Chinese Society for Diseases of the Esophagus. [Chinese Guidelines on Perioperative Management of Resectable Esophageal Cancer (2023 edition)]. Zhonghua Yi Xue Za Zhi 103, 2552–2570 (2023).Kitagawa, Y.

中国国家癌症中心；中国胸外科医师协会；中国胸心血管外科学会；中国食道疾病学会。[中国可切除食管癌围手术期管理指南（2023年版）]。中华医学杂志1032552-2570（2023）。北川，Y。

et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus 20, 343–372 (2023).Article .

等人。日本食管学会编辑的2022年食管癌实践指南：第1部分。食道20343-372（2023）。文章。

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

van Hagen, P. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366, 2074–2084 (2012).Article

van Hagen，P。等人。食管癌或交界癌的术前放化疗。N、 英语。J、 医学3662074-2084（2012）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Yang, H. et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the Esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial. J. Clin. Oncol. 36, 2796–2803 (2018).Article

Yang，H.等。局部晚期食管鳞状细胞癌的新辅助放化疗后手术与单纯手术（NEOCRTEC5010）：一项III期多中心，随机，开放标签临床试验。J、 临床。Oncol公司。362796-2803（2018）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Ando, N. et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann. Surg. Oncol. 19, 68–74 (2012).Article

一项比较顺铂和5-氟尿嘧啶术后辅助化疗与术前化疗治疗胸段食管局部晚期鳞状细胞癌的随机试验（JCOG9907）。安。外科。Oncol。19,68-74（2012）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Tang, H. et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann. Oncol. 34, 163–172 (2023).Article

Tang，H.等。新辅助放化疗与新辅助化疗后微创食管切除术治疗局部晚期食管鳞状细胞癌：一项前瞻性多中心随机临床试验。安科。34163-172（2023）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Kato, K. et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J. Clin. Oncol. 40, 238–238 (2022).Article

Kato，K.等人，《一项比较两种化疗方案和放化疗方案作为局部晚期食管癌新辅助治疗的随机对照III期临床试验》，JCOG1109 NExT研究。J、 临床。Oncol公司。。文章

Google Scholar

谷歌学者

Faron, M. et al. Individual participant data network meta-analysis of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastroesophageal junction carcinoma. J. Clin. Oncol. 41, 4535–4547 (2023).Article

Faron，M.等。食管癌或胃食管交界癌新辅助化疗或放化疗的个体参与者数据网络荟萃分析。J、 临床。Oncol公司。414535-4547（2023）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Huang, J. et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 21, 832–842 (2020).Article

Huang，J.等人，Camrelizumab与研究者选择化疗作为晚期或转移性食管鳞状细胞癌（ESCORT）的二线治疗：一项多中心，随机，开放标签的3期研究。柳叶刀Oncol。21832-842（2020）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Luo, H. et al. Effect of Camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 326, 916–925 (2021).Article

Luo，H.等人。卡姆雷珠单抗与安慰剂联合化疗对晚期或转移性食管鳞状细胞癌患者生存率和无进展生存率的影响：ESCORT-1st随机临床试验。JAMA 326916–925（2021）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Yang, Y. et al. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study). Int. J. Surg. 110, 1430–1440 (2024).Article

Yang，Y.等。新辅助卡美利珠单抗联合紫杉醇和奈达铂治疗局部晚期食管鳞状细胞癌：单臂2期研究（队列研究）。《国际外科杂志》1101430-1440（2024）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Liu, J. et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study. Int. J. Cancer 151, 128–137 (2022).Article

Liu，J.等。新辅助卡美利珠单抗联合化疗治疗可切除的局部晚期食管鳞状细胞癌（NIC-ESCC2019）：一项多中心2期研究。《国际癌症杂志》151128-137（2022）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Liu, J. et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J. Immunother. Cancer 10, e004291 (2022).Article

Liu，J.等。camrelizumab和化疗作为局部晚期食管鳞状细胞癌新辅助治疗的多中心单臂II期临床试验。J、 免疫疗法。癌症10，e004291（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Yang, W. et al. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. J. Immunother. Cancer 10, e003497 (2022).Article

Yang，W。等。新辅助程序性细胞死亡1阻断联合化疗治疗可切除的食管鳞状细胞癌。J、 免疫疗法。癌症10，e003497（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Wang, Z. et al. Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma. J. Natl Cancer Cent. 2, 98–105 (2022).Article

Wang，Z.等。camrelizumab联合化疗和阿帕替尼新辅助治疗局部晚期胸段食管鳞状细胞癌的Ib期临床试验。J、 自然癌症分。2，98-105（2022）。文章

CAS

中科院

Google Scholar

谷歌学者

Gong, L. et al. Camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II trial. J. Clin. Oncol. 41, 4048–4048 (2023).Article

Gong，L.等人。Camrelizumab和化疗作为局部晚期食管鳞状细胞癌（ESCC）的新辅助治疗：单臂II期试验。J、 临床。Oncol公司。414048-4048（2023）。文章

Google Scholar

谷歌学者

Yu, Y. K. et al. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. J. Thorac. Cardiovasc. Surg. 2024, S0022-5223(24)00008-4 (2024).Yang, Y. et al. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.

Yu，Y.K.等。局部晚期食管鳞状细胞癌患者新辅助化疗联合免疫治疗与新辅助放化疗的比较。J、 胸部。。外科2024，S0022-5223（24）00008-4（2024）。Yang，Y。等。新辅助nab-紫杉醇联合免疫疗法与紫杉醇联合免疫疗法治疗食管鳞状细胞癌的比较。

Thorac. Cancer 14, 700–708 (2023).Article .

胸部。癌症14700-708（2023）。文章。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Gaber, C. E. et al. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a systematic review and meta-analysis. Cancer Med. 13, e7076 (2024).Article

Gaber，C.E.等人。接受新辅助化疗或放化疗的食管癌患者的病理完全缓解：系统评价和荟萃分析。癌症医学13，e7076（2024）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Oppedijk, V. et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J. Clin. Oncol. 32, 385–391 (2014).Article

Oppedijk，V。等人。交叉试验中单独手术与术前放化疗和手术后复发的模式。J、 临床。Oncol公司。32385-391（2014）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Cools-Lartigue, J. et al. An international cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma. Ann. Surg. 276, 799–805 (2022).Article

Cools-Lartigue，J.等人。一项国际队列研究，研究新辅助化疗与手术治疗食管腺癌放化疗后病理完全缓解的预后。《外科杂志》276799-805（2022）。文章

PubMed

PubMed

Google Scholar

谷歌学者

Topalian, S. L., Taube, J. M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).Article

Topalian，S.L.，Taube，J.M。和Pardoll，D.M。癌症免疫治疗的新辅助检查点封锁。科学367，eaax0182（2020）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Shitara, K. et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 25, 212–224 (2024).Article

Shitara，K。等。局部晚期胃癌或胃食管癌的新辅助和辅助pembrolizumab加化疗（KEYNOTE-585）：多中心，双盲，随机3期研究的中期分析。柳叶刀Oncol。25212-224（2024）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023).Article

Rha，S.Y.等人，Pembrolizumab联合化疗与安慰剂联合化疗治疗HER2阴性晚期胃癌（KEYNOTE-859）：一项多中心，随机，双盲，3期临床试验。柳叶刀Oncol。241181-1195（2023）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).Article

Janjigian，Y.Y.等人。一线nivolumab加化疗与单纯化疗治疗晚期胃，胃食管交界处和食管腺癌（CheckMate 649）：一项随机，开放标签的3期临床试验。。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Janjigian, Y. Y. et al. LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Ann. Oncol.

Janjigian，Y.Y.等人，LBA73在可切除的胃和胃食管交界癌（GC/GEJC）中对durvalumab加5-氟尿嘧啶，亚叶酸钙，奥沙利铂和多西紫杉醇（FLOT）的病理完全缓解（pCR）：全球III期MATTERHORN研究的中期结果。安科。

34, S1315–S1316 (2023).Article .

34，S1315–S1316（2023）。文章。

Google Scholar

谷歌学者

Lorenzen, S. et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 Trial. J. Clin. Oncol. 42, 410–420 (2024).Article

Lorenzen，S.等。围手术期atezolizumab联合氟尿嘧啶、亚叶酸钙、奥沙利铂和多西紫杉醇治疗可切除食管胃癌：随机、多中心、II/III期DANTE/IKF-s633试验的中期结果。J、 临床。Oncol公司。42410-420（2024）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Ge, F. et al. Evaluation of clinical and safety outcomes of neoadjuvant immunotherapy combined with chemotherapy for patients with resectable esophageal cancer: a systematic review and meta-analysis. JAMA Netw. Open 5, e2239778 (2022).Article

。JAMA网络。打开5，e2239778（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Eads, J. R. et al. A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: a trial of the ECOG-ACRIN Cancer Research Group (EA2174). J. Clin. Oncol. 38, TPS4651–TPS4651 (2020).Article .

。J、 临床。Oncol公司。38，TPS4651–TPS4651（2020）。文章。

Google Scholar

谷歌学者

Cancer Genome Atlas Research, N. et al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).Article

癌症基因组图谱研究，N。等人。食管癌的综合基因组表征。自然541169-175（2017）。文章

Google Scholar

谷歌学者

Shang, X. et al. Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed by surgery for locally advanced oesophageal squamous cell carcinoma: protocol for a multicentre, prospective, randomized-controlled, phase III clinical study (Keystone-002).

Shang，X。等人。Pembrolizumab联合新辅助化疗与新辅助放化疗，然后手术治疗局部晚期食管鳞状细胞癌：多中心，前瞻性，随机对照，III期临床研究方案（Keystone-002）。

Front Oncol. 12, 831345 (2022).Article .

前部Oncol。。文章。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Arbour, K. C. et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J. Clin. Oncol. 36, 2872–2878 (2018).Article

Arbour，K.C.等人。基线类固醇对非小细胞肺癌患者程序性细胞死亡-1和程序性死亡配体1阻断疗效的影响。J、 临床。Oncol公司。362872-2878（2018）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).Article

Im，S.J.等人定义了在PD-1治疗后提供增殖爆发的CD8+T细胞。。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Untch, M. et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. 17, 345–356 (2016).Article

Untch，M.等人，《Nab紫杉醇与溶剂型紫杉醇在早期乳腺癌新辅助化疗中的对比研究》（GeparSepto GBG 69）：一项随机的3期临床试验。柳叶刀Oncol。17345-356（2016）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Franzoi, M. A. & de Azambuja, E. Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? ESMO Open 5, e001112 (2020).Article

Franzoi，M.A。和de Azambuja，E。Atezolizumab治疗转移性三阴性乳腺癌：IMPASION130和131试验-如何解释不同的结果？ESMO公开赛5，e001112（2020）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).Article

Paz-Ares，L.等人，Pembrolizumab联合化疗治疗鳞状非小细胞肺癌。N、 英语。J、 医学3792040-2051（2018）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Zong, Y., Wu, J. & Shen, K. Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget 8, 17360–17372 (2017).Article

Zong，Y.，Wu，J。＆Shen，K。纳米粒子白蛋白结合紫杉醇作为乳腺癌的新辅助化疗：系统评价和荟萃分析。Oncotarget817360–17372（2017）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Liu, M., Liu, S., Yang, L. & Wang, S. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. BMC Cancer 21, 118 (2021).Article

Liu，M.，Liu，S.，Yang，L。＆Wang，S。nab-紫杉醇和溶剂型紫杉烷作为乳腺癌新辅助治疗的比较：系统评价和荟萃分析。BMC癌症21118（2021）。文章

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Kojima, T. et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38, 4138–4148 (2020).Article

Kojima，T。等人。pembrolizumab与晚期食管癌化疗的随机III期KEYNOTE-181研究。J、 临床。Oncol公司。。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759–771 (2021).Article

Sun，J.M.等人，《Pembrolizumab联合化疗与单纯化疗治疗晚期食管癌的一线治疗》（KEYNOTE-590）：一项随机、安慰剂对照的3期研究。柳叶刀398759-771（2021）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Wu, H. X. et al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J. Clin. Oncol. 41, 1735–1746 (2023).Article

Wu，H.X.等人。一线程序性死亡-1抗体加化疗在低程序性细胞死亡配体1表达的食管鳞状细胞癌中的临床益处：JUPITER-06的事后分析和荟萃分析。J、 临床。Oncol公司。411735-1746（2023）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Eyck, B. M. et al. Pathological response to neoadjuvant chemoradiotherapy for oesophageal squamous cell carcinoma: multicentre East Asian and Dutch database comparison. Br. J. Surg. 109, 1312–1318 (2022).Article

Eyck，B.M.等。食管鳞状细胞癌新辅助放化疗的病理反应：多中心东亚和荷兰数据库比较。《英国外科杂志》1091312-1318（2022）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Chen, Y. et al. Does major pathological response after neoadjuvant Immunotherapy in resectable nonsmall-cell lung cancers predict prognosis? A systematic review and meta-analysis. Int. J. Surg. 109, 2794–2807 (2023).Article

Chen，Y.等。可切除非小细胞肺癌新辅助免疫治疗后的主要病理反应是否可以预测预后？。《国际外科杂志》1092794-2807（2023）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Gianni, L. et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann. Oncol. 33, 534–543 (2022).Article

。安科。33534-543（2022）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Wang, H. Y. et al. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco Targets Ther. 9, 5663–5669 (2016).Article .

Wang，H.Y.等人。每周纳米颗粒白蛋白结合紫杉醇联合顺铂与每周溶剂型紫杉醇联合顺铂作为中国晚期食管鳞状细胞癌患者的一线治疗。Onco以Ther为目标。95663-5669（2016）。文章。

CAS

中科院

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Kang, X. et al. NCC/CATS/CSTCVS/STM expert consensus on perioperative immunotherapy for esophageal cancer. Ann. Esophagus 4, AOE6504 (2021).Article

Kang，X。等。NCC/CATS/CSTCVS/STM食管癌围手术期免疫治疗专家共识。安。食道4，AOE6504（2021）。文章

Google Scholar

谷歌学者

Mandard, A. M. et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73, 2680–2686 (1994).Article

Mandard，A.M.等人。食管癌术前放化疗后肿瘤消退的病理评估。临床病理相关性。癌症732680-2686（1994）。文章

CAS

中科院

PubMed

PubMed

Google Scholar

谷歌学者

Low, D. E. et al. International consensus on standardization of data collection for complications associated with esophagectomy: esophagectomy complications consensus group (ECCG). Ann. Surg. 262, 286–294 (2015).Article

Low，D.E.等人，《关于食管切除术并发症数据收集标准化的国际共识：食管切除术并发症共识小组》（ECCG）。。文章

PubMed

PubMed

Google Scholar

谷歌学者

Dindo, D., Demartines, N. & Clavien, P. A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg. 240, 205–213 (2004).Article

Dindo，D.，Demartines，N。＆Clavien，P.A。手术并发症的分类：一项新的提案，对6336名患者进行了评估，并得出了调查结果。《外科杂志》240205-213（2004）。文章

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAcknowledgementsThis study was funded by Jiangsu Hengrui Pharmaceuticals. The sponsor was involved in the collection, analysis and interpretation of data, as well as in the preparation of the manuscript. We extend our gratitude to all patients who participated in this trial and their families, as well as the researchers and staff at each study center for their invaluable contributions.

下载参考文献致谢本研究由江苏恒瑞制药资助。赞助商参与了数据的收集，分析和解释，以及手稿的准备。我们感谢所有参与该试验的患者及其家属，以及每个研究中心的研究人员和工作人员做出的宝贵贡献。

We thank Chi Ma, Feng Zhao, Jin Yan, Aichun Chen (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals) and Chenxuan Liu (former employee of Jiangsu Hengrui Pharmaceuticals) for data interpretation, and Ni Guan (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals) for statistical support.

我们感谢Chi Ma，Feng Zhao，Jin Yan，Aichun Chen（江苏恒瑞制药医务部）和Chenxuan Liu（江苏恒瑞制药前员工）的数据解释，以及Ni Guan（江苏恒瑞制药医务部）的统计支持。

Medical writing support was provided by Fangzhou Xia and Zhongjiang Chen (Department of Medical Affairs, Jiangsu Hengrui Pharmaceuticals) according to good publication practice guidelines.Author informationAuthor notesThese authors contributed equally: Jianjun Qin, Liyan Xue.Authors and AffiliationsSection of Esophageal and Mediastinal Oncology, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaJianjun Qin, Xiaozheng Kang, Ruixiang Zhang, Yong Li, Zhen Wang, Xiankai Chen, Jie He & Yin LiDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaLiyan Xue & Zhaoyang YangDepartment of Thoracic Surgery, Anyang Cancer Hospital, Anyang, ChinaAnlin Hao & Xiaofeng GuoDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Military Medical University, Xi’an, ChinaTao Jiang .

夏方舟和陈中江（江苏恒瑞制药医务部）根据良好出版实践指南提供了医学写作支持。作者信息作者注意到这些作者做出了同样的贡献：秦建军，薛丽燕。作者和所属单位中国医学科学院北京协和医学院国家癌症中心/国家癌症临床研究中心/北京协和医院胸外科食管和纵隔肿瘤科秦建军、康晓正、张瑞祥、李勇、王震、陈先凯、何洁和尹丽中国医学科学院北京协和医学院国家癌症中心/国家癌症临床研究中心病理科北京安阳肿瘤医院胸外科，安阳，中国空军军事医科大学唐都医院胸外科中国西安陶江。

PubMed Google ScholarLiyan XueView author publicationsYou can also search for this author in

PubMed Google ScholarLiyan XueView作者出版物您也可以在

PubMed Google ScholarAnlin HaoView author publicationsYou can also search for this author in

PubMed Google ScholarAnlin HaoView作者出版物您也可以在

PubMed Google ScholarXiaofeng GuoView author publicationsYou can also search for this author in

PubMed Google ScholarXiaofeng GuoView作者出版物您也可以在

PubMed Google ScholarTao JiangView author publicationsYou can also search for this author in

PubMed Google ScholarTao JiangView作者出版物您也可以在

PubMed Google ScholarYunfeng NiView author publicationsYou can also search for this author in

PubMed Google ScholarYunfeng NiView作者出版物您也可以在

PubMed Google ScholarShuoyan LiuView author publicationsYou can also search for this author in

PubMed Google ScholarYujie ChenView author publicationsYou can also search for this author in

PubMed Google ScholarYujie ChenView作者出版物您也可以在

PubMed Google ScholarHongjing JiangView author publicationsYou can also search for this author in

PubMed Google ScholarHongjing JiangView作者出版物您也可以在

PubMed Google ScholarChen ZhangView author publicationsYou can also search for this author in

PubMed Google ScholarChen ZhangView作者出版物您也可以在

PubMed Google ScholarMingqiang KangView author publicationsYou can also search for this author in

PubMed Google Scholarmamingqiang KangView作者出版物您也可以在

PubMed Google ScholarJihong LinView author publicationsYou can also search for this author in

PubMed谷歌学者Jihong LinView作者出版物您也可以在

PubMed Google ScholarHecheng LiView author publicationsYou can also search for this author in

PubMed Google ScholarHecheng LiView作者出版物您也可以在

PubMed Google ScholarChengqiang LiView author publicationsYou can also search for this author in

PubMed Google ScholarChengqiang LiView作者出版物您也可以在

PubMed Google ScholarHui TianView author publicationsYou can also search for this author in

PubMed谷歌学术期刊Hui TianView作者出版物您也可以在中搜索此作者。的信息。的研究报告中找到该作者。的信息。的研究报告。的研究报告。的研究报告中，该研究报告的作者为一位来自美国的研究人员，该研究报告的作者为一位

PubMed Google ScholarLin LiView author publicationsYou can also search for this author in

PubMed Google ScholarLin LiView作者出版物您也可以在

PubMed Google ScholarJunke FuView author publicationsYou can also search for this author in

PubMed Google ScholarJunke FuView作者出版物您也可以在

PubMed Google ScholarYong ZhangView author publicationsYou can also search for this author in

PubMed Google ScholarYong ZhangView作者出版物您也可以在

PubMed Google ScholarJianqun MaView author publicationsYou can also search for this author in

PubMed Google ScholarJianqun MaView作者出版物您也可以在

PubMed Google ScholarXiaoyuan WangView author publicationsYou can also search for this author in

PubMed谷歌学者Xiaoyuan WangView作者出版物您也可以在

PubMed Google ScholarMaoyong FuView author publicationsYou can also search for this author in

PubMed Google ScholarMaoyong FuView作者出版物您也可以在

PubMed Google ScholarHao YangView author publicationsYou can also search for this author in

PubMed Google ScholarZhaoyang YangView author publicationsYou can also search for this author in

PubMed谷歌学者赵阳YangView作者出版物您也可以在

PubMed Google ScholarYongtao HanView author publicationsYou can also search for this author in

PubMed Google ScholarYongtao HanView作者出版物您也可以在

PubMed Google ScholarLongqi ChenView author publicationsYou can also search for this author in

PubMed Google ScholarLongqi ChenView作者出版物您也可以在

PubMed Google ScholarLijie TanView author publicationsYou can also search for this author in

PubMed Google ScholarLijie TanView作者出版物您也可以在

PubMed Google ScholarTianyang DaiView author publicationsYou can also search for this author in

PubMed Google ScholarTianyang DaiView作者出版物您也可以在

PubMed Google ScholarYongde LiaoView author publicationsYou can also search for this author in

PubMed Google ScholarYongde LiaoView作者出版物您也可以在

PubMed Google ScholarWeiguo ZhangView author publicationsYou can also search for this author in

PubMed Google ScholarWeiguo ZhangView作者出版物您也可以在

PubMed Google ScholarBin LiView author publicationsYou can also search for this author in

PubMed Google ScholarBin LiView作者出版物您也可以在

PubMed Google ScholarQixun ChenView author publicationsYou can also search for this author in

PubMed谷歌学者陈启勋查看作者出版物您也可以在

PubMed Google ScholarShiping GuoView author publicationsYou can also search for this author in

PubMed Google ScholarShiping GuoView作者出版物您也可以在

PubMed Google ScholarYu QiView author publicationsYou can also search for this author in

PubMed Google ScholarYu QiView作者出版物您也可以在

PubMed Google ScholarLi WeiView author publicationsYou can also search for this author in

PubMed Google ScholarLi WeiView作者出版物您也可以在

PubMed Google ScholarZhigang LiView author publicationsYou can also search for this author in

PubMed Google ScholarZhigang LiView作者出版物您也可以在

PubMed Google ScholarZiqiang TianView author publicationsYou can also search for this author in

PubMed谷歌学者Ziqiang TianView作者出版物您也可以在

PubMed Google ScholarXiaozheng KangView author publicationsYou can also search for this author in

PubMed Google ScholarXiaozheng KangView作者出版物您也可以在

PubMed Google ScholarRuixiang ZhangView author publicationsYou can also search for this author in

PubMed Google ScholarRuixiang ZhangView作者出版物您也可以在

PubMed Google ScholarYong LiView author publicationsYou can also search for this author in

PubMed Google ScholarYong LiView作者出版物您也可以在

PubMed Google ScholarZhen WangView author publicationsYou can also search for this author in

PubMed Google ScholarZhen WangView作者出版物您也可以在

PubMed Google ScholarXiankai ChenView author publicationsYou can also search for this author in

PubMed谷歌学者陈先凯查看作者出版物您也可以在

PubMed Google ScholarZhiguo HouView author publicationsYou can also search for this author in

PubMed谷歌学者Zhiguo HouView作者出版物您也可以在

PubMed Google ScholarRongrong ZhengView author publicationsYou can also search for this author in

PubMed Google ScholarRongrong ZhengView作者出版物您也可以在

PubMed Google ScholarWenqing ZhuView author publicationsYou can also search for this author in

PubMed谷歌学者朱文清查看作者出版物您也可以在

PubMed Google ScholarJie HeView author publicationsYou can also search for this author in

PubMed Google ScholarJie HeView作者出版物您也可以在

PubMed Google ScholarYin LiView author publicationsYou can also search for this author in

PubMed Google ScholarYin LiView作者出版物您也可以在

PubMed Google ScholarContributionsJ.Q. and L.X. contributed equally to this work. Yin Li, J.H., J.Q., Z.H., and R. Zheng were responsible for the conception and design of the study. Yin Li, J.Q., L.X., A.H., X.G., T.J., Y.N., S.L., Y.C., H.J., C.Z., M.K., J.L., H.L., C.L., H.T., L.L., J.F., Y.Z., J.M., X.W., M.F., H.Y., Z.Y., Y.H., L.C., L.T., T.D., Y.

PubMed谷歌学术贡献。Q、 和L.X.对这项工作做出了同样的贡献。Yin Li，J.H.，J.Q.，Z.H。和R.Zheng负责这项研究的概念和设计。尹丽，J.Q.，L.X.，A.H.，X.G.，T.J.，Y.N.，S.L.，Y.C.，H.J.，C.Z.，M.K.，J.L.，H.L.，C.L.，H.T.，L.L.，J.F.，Y.Z.，J.M.，X.W.，M.F.，H.Y.，Z.Y.，Y.H.，L.C.，L.T.，T.D.，Y。

Liao, W.Z., B.L., Q.C., S.G., Y.Q., L.W., Z.L., Z.T., X.K., R. Zhang, Yong Li, Z.W., and X.C. contributed to data collection. W.Z. directed the statistical analysis. All authors were involved in data interpretation, manuscript writing, review, and approved the final manuscript for submission.Corresponding authorsCorrespondence to.

Liao，W.Z.，B.L.，Q.C.，S.G.，Y.Q.，L.W.，Z.L.，Z.T.，X.K.，R.Zhang，Yong Li，Z.W。和X.C.为数据收集做出了贡献。W、 Z.指导统计分析。所有作者都参与了数据解释，稿件撰写，审查，并批准了最终稿件的提交。通讯作者通讯。

Jie He or Yin Li.Ethics declarations

何洁或尹莉。道德宣言

Competing interests

相互竞争的利益

Z.H., R. Zheng and W.Z. are employees of Jiangsu Hengrui Pharmaceuticals. The other authors declare no competing interests.

Z、 H.，R.Zheng和W.Z.是江苏恒瑞制药的员工。其他作者声明没有利益冲突。

Peer review

同行评审

Peer review information

同行评审信息

Nature Medicine thanks Ken Kato, Nataliya Uboha and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Saheli Sadanand, in collaboration with the Nature Medicine team.

《自然医学》感谢Ken Kato、Nataliya Uboha和另一位匿名审稿人为这项工作的同行评审做出的贡献。主要处理编辑：Saheli Sadanand，与《自然医学》团队合作。

Additional informationPublisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Extended dataExtended Data Fig. 1 Post hoc subgroup analysis of pCR between Cam+nab-TP group and TP group.The central points on each bar represent the mean difference in pCR rates between the two groups, while the bars indicate the 95% CI.

Additional informationPublisher的注释Springer Nature在已发布的地图和机构隶属关系中的管辖权主张方面保持中立。扩展数据扩展数据图1 Cam+nab-TP组和TP组之间pCR的事后亚组分析。每个条上的中心点代表两组之间pCR率的平均差异，而条表示95%CI。

pCR, pathological complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; TPS, tumor proportion score; CPS, combined positive score; CI, confidence interval.Extended Data Fig. 2 Post hoc subgroup analysis of pCR between Cam+TP group and TP group.The central points on each bar represent the mean difference in pCR rates between the two groups, while the bars indicate the 95% CI.

；ECOG PS，东部肿瘤协作组的表现状况；TPS，肿瘤比例评分；CPS，综合阳性评分；CI，置信区间。扩展数据图2 Cam+TP组和TP组之间pCR的事后亚组分析。每个条上的中心点代表两组之间pCR率的平均差异，而条表示95%CI。

pCR, pathological complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; TPS, tumor proportion score; CPS, combined positive score; CI, confidence interval.Extended Data Fig. 3 Depth of pathological regression in primary tumor.(a) Cam+nab-TP group, (b) Cam+TP group and (c) TP group.

；ECOG PS，东部肿瘤协作组的表现状况；TPS，肿瘤比例评分；CPS，综合阳性评分；CI，置信区间。扩展数据图3原发肿瘤病理消退的深度。（a） Cam+nab-TP组，（b）Cam+TP组和（c）TP组。

RVT, residual viable tumor cells; IQR, interquartile range.Supplementary informationSupplementary InformationSupplementary Tables 1–5, study protocol and statistical analysis plan.Reporting SummaryRights and permissions.

RVT，残留的活肿瘤细胞；IQR，四分位间距。补充信息补充信息补充表1-5，研究方案和统计分析计划。。

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

开放获取本文是根据知识共享署名4.0国际许可证授权的，该许可证允许以任何媒体或格式使用，共享，改编，分发和复制，只要您对原始作者和来源给予适当的信任，提供知识共享许可证的链接，并指出是否进行了更改。

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非在材料的信用额度中另有说明。。

To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/..

要查看此许可证的副本，请访问http://creativecommons.org/licenses/by/4.0/..

Reprints and permissionsAbout this articleCite this articleQin, J., Xue, L., Hao, A. et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial.

转载和许可本文引用本文Qin，J.，Xue，L.，Hao，A。等人。在可切除的食管鳞状细胞癌中使用或不使用camrelizumab的新辅助化疗：随机3期ESCORT-NEO/NCCES01试验。

Nat Med (2024). https://doi.org/10.1038/s41591-024-03064-wDownload citationReceived: 29 March 2024Accepted: 13 May 2024Published: 02 July 2024DOI: https://doi.org/10.1038/s41591-024-03064-wShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Med（2024）。https://doi.org/10.1038/s41591-024-03064-wDownload引文接收日期：2024年3月29日接受日期：2024年5月13日发布日期：2024年7月2日OI：https://doi.org/10.1038/s41591-024-03064-wShare本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供